DAMORA THERAPEUTICS, INC. Payments to Acquire Debt Securities, Available-for-sale
DAMORA THERAPEUTICS, INC. (DMRA) reported Payments to Acquire Debt Securities, Available-for-sale of $25.94 million for the 12-month period ending 2023-12-31, per its 10-K filed 2025-03-19.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2025-03-19
- DAMORA THERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2023-12-31 was $0.00, a 100.00% decline year-over-year.
- DAMORA THERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2023-09-30 was $3.94M.
- DAMORA THERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2023-06-30 was $9.24M, a 35.23% decline year-over-year.
- DAMORA THERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2023-03-31 was $12.75M, a 51.67% decline year-over-year.
- DAMORA THERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for fiscal 2023 was $25.94M, a 42.19% decline from fiscal 2022.
- DAMORA THERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for fiscal 2022 was $44.87M, a 46.72% decline from fiscal 2021.
- DAMORA THERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for fiscal 2021 was $84.21M.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 3 month | Payments to Acquire Debt Securities, Available-for-sale 6 month | Payments to Acquire Debt Securities, Available-for-sale 9 month | Payments to Acquire Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-19 | $3.94M derived: sum of 2 quarters · filed 2025-03-19 | $13.19M derived: sum of 3 quarters · filed 2025-03-19 | $25.94M 10-K · filed 2025-03-19 |
| 2023-09-30 | $3.94M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-01 | $13.19M derived: sum of 2 quarters · filed 2024-11-01 | $25.94M 10-Q · filed 2024-11-01 | $30.15M derived: sum of 4 quarters · filed 2024-11-01 |
| 2023-06-30 | $9.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $21.99M 10-Q · filed 2024-08-12 | $26.20M derived: sum of 3 quarters · filed 2024-08-12 | $26.20M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $12.75M 10-Q · filed 2024-04-29 | $16.96M derived: sum of 2 quarters · filed 2024-04-29 | $16.96M derived: sum of 3 quarters · filed 2024-04-29 | $31.23M derived: sum of 4 quarters · filed 2024-04-29 |
| 2022-12-31 | $4.21M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-08 | $4.21M derived: sum of 2 quarters · filed 2024-03-08 | $18.48M derived: sum of 3 quarters · filed 2024-03-08 | $44.87M 10-K · filed 2024-03-08 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | $14.27M derived: sum of 2 quarters · filed 2023-11-06 | $40.66M 10-Q · filed 2023-11-06 | $40.66M derived: sum of 4 quarters · filed 2023-11-06 |
| 2022-06-30 | $14.27M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-07-31 | $40.66M 10-Q · filed 2023-07-31 | $40.66M derived: sum of 3 quarters · filed 2023-07-31 | $43.81M derived: sum of 4 quarters · filed 2023-07-31 |
| 2022-03-31 | $26.39M 10-Q · filed 2023-04-28 | $26.39M derived: sum of 2 quarters · filed 2023-04-28 | $29.54M derived: sum of 3 quarters · filed 2023-04-28 | $36.03M derived: sum of 4 quarters · filed 2023-04-28 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $3.16M derived: sum of 2 quarters · filed 2023-03-09 | $9.64M derived: sum of 3 quarters · filed 2023-03-09 | $84.21M 10-K · filed 2023-03-09 |
| 2021-09-30 | $3.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $9.64M derived: sum of 2 quarters · filed 2022-11-08 | $84.21M 10-Q · filed 2022-11-08 | |
| 2021-06-30 | $6.49M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-07-29 | $81.05M 10-Q · filed 2022-07-29 | ||
| 2021-03-31 | $74.57M 10-Q · filed 2022-04-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |